Postoperative complications in women with ovarian cancer stratified by cytoreductive surgery outcome.
cytoreduction
debulking
no gross residual
optimal
ovarian cancer
suboptimal
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
26
05
2023
received:
27
12
2022
accepted:
03
06
2023
pmc-release:
01
10
2024
medline:
11
9
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
To compare 30-day postoperative complications for patients with advanced ovarian cancer who underwent resection to no gross residual disease versus optimal and suboptimal cytoreduction. A retrospective cohort study of women drawn from the National Surgical Quality Improvement Program who underwent cytoreductive surgery for advanced ovarian cancer between 2014 and 2019 was performed. Exposure of interest was extent of surgical resection defined as no gross residual disease; residual disease <1 cm (optimal); and residual disease >1 cm (suboptimal). Primary outcome was postoperative complication. Associations were examined with bivariable tests and multivariable logistic regression. A total of 2248 women underwent cytoreductive surgery; 68.4% (n = 1538) underwent resection to no gross residual disease, 22.4% (n = 504) had an optimal, and 9.2% (n = 206) had a suboptimal cytoreduction. Optimal cytoreduction patients had the highest rates of any postoperative complication (35.5%, p < 0.001). They also had the longest operative times and procedures that were most surgically complex (203 min, 43.6 relative value units, both p < 0.05). However, patients who underwent optimal cytoreduction did not have increased odds of major complications (adjusted odds ratio: 1.20, 95% confidence interval: 0.91-1.58). Patients who underwent optimal cytoreduction had more postoperative complications, required the most operating room time, and represented more complex surgeries compared with suboptimal cytoreduction or resection to no gross residual disease.
Identifiants
pubmed: 37382209
doi: 10.1002/jso.27380
pmc: PMC10529113
mid: NIHMS1917780
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
891-901Subventions
Organisme : NIA NIH HHS
ID : P30 AG059988
Pays : United States
Organisme : NIA NIH HHS
ID : R03 AG074031
Pays : United States
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Gynecol Oncol. 2009 Jul;114(1):26-31
pubmed: 19395008
Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007565
pubmed: 21833960
Obstet Gynecol. 2006 Jan;107(1):77-85
pubmed: 16394043
Gynecol Oncol. 2017 Feb;144(2):260-265
pubmed: 27908531
Eur J Cancer. 2010 Jan;46(1):102-9
pubmed: 19900801
Gynecol Oncol. 2011 Dec;123(3):467-73
pubmed: 21958535
Gynecol Oncol. 2015 Dec;139(3):394-400
pubmed: 26348314
Gynecol Oncol. 2007 Oct;107(1):99-106
pubmed: 17602726
Eur J Cancer. 2016 May;59:22-33
pubmed: 26998845
Gynecol Oncol. 2009 Sep;114(3):523-7
pubmed: 19344936
J Clin Oncol. 2015 Mar 10;33(8):937-43
pubmed: 25667285
Gynecol Oncol. 2013 Sep;130(3):493-8
pubmed: 23747291
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Gynecol Oncol. 2016 Jan;140(1):15-21
pubmed: 26541980
Gynecol Oncol. 2010 Oct;119(1):38-42
pubmed: 20609464
Gynecol Oncol. 2019 Aug;154(2):283-289
pubmed: 31196575
J Am Coll Surg. 2010 Jan;210(1):6-16
pubmed: 20123325
Gynecol Oncol. 2003 Aug;90(2):390-6
pubmed: 12893206
J Surg Res. 2020 Feb;246:34-41
pubmed: 31561176
Am J Obstet Gynecol. 2019 Mar;220(3):263.e1-263.e8
pubmed: 30521798